J. Gutierrez

发表

New antiviral agents for the treatment of hepatitis C: ABT-450

Paul L. Martin, Andres F Carrion, J. Gutierrez, 2014, Expert opinion on pharmacotherapy.

Hepatitis C Virus and End Stage Renal Disease

H. Patton, J. Gutierrez, 2011 .

Influenza Vaccination in Orthotopic Liver Transplant Recipients: Absence of Post Administration ALT Elevation

A. Branch, T. Schiano, M. Schwartz, 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Classical and emerging roles of vitamin D in hepatitis C virus infection.

A. Branch, N. Parikh, J. Gutierrez, 2011, Seminars in liver disease.

Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C

Paul L. Martin, J. Gutierrez, Juan Trivella, 2015, Expert opinion on pharmacotherapy.

Interferon‐free, direct‐acting antiviral therapy for chronic hepatitis C

E. Lawitz, F. Poordad, J. Gutierrez, 2015, Journal of viral hepatitis.

Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression.

R. Schooley, A. Singhania, C. Woelk, 2014, Journal of virology & antiviral research.

Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment.

N. Mathur, J. Gutierrez, Vanessa C. Costilla, 2015, Clinics in liver disease.

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

Paul L. Martin, Andres F Carrion, C. O'brien, 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

B. Neuschwander‐Tetri, G. Gores, J. Wayne, 2021, Gastroenterology.

Sofosbuvir‐velpatasvir‐voxilaprevir with or without ribavirin in direct‐acting antiviral–experienced patients with genotype 1 hepatitis C virus

H. Dvory‐Sobol, D. Brainard, J. McHutchison, 2017, Hepatology.

Superior vena cava syndrome secondary to syphilitic aneurysm of the ascending aorta in a human immunodeficiency virus-infected patient.

J. Gutierrez, J. F. Val, M. Fernández-Ayala, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Human Peritoneal Macrophages From Ascitic Fluid Can be Infected by a Broad Range of HIV-1 Isolates

A. Branch, T. Schiano, Theresa L. Chang, 2010, Journal of acquired immune deficiency syndromes.

Lorcaserin Use in the Management of Morbid Obesity in a Pre‐Liver Transplant Patient

F. Poordad, J. Wells, Carmen E. Landaverde, 2016, Hepatology.

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease

P. V. Remoortere, S. Ouwerkerk-Mahadevan, V. van Eygen, 2017, Journal of viral hepatitis.

Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.

A. Branch, D. Dieterich, K. Childs, 2010, AIDS research and human retroviruses.

The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others.

D. Stump, A. Branch, F. Eng, 2005, Seminars in liver disease.

Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors

A. Branch, C. Bodian, T. Schiano, 2005, Hepatology.

Andres F Carrion, K. Bhamidimarri, J. Gutierrez, 2015 .

Reply: To PMID 25825070.

Andres F Carrion, K. Bhamidimarri, J. Gutierrez, 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions.

D. Stump, A. Branch, G. Benson, 2002, RNA.

Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules.

R. Gish, J. Gutierrez, 2013, Translational cancer research.

C-Swift Retreatment Final Results: Highly Successful Retreatment of GT1-Infected Patients with 12 Weeks of Elbasvir/Grazoprevir plus Sofosbuvir and Ribavirin after Failure of Short-Duration All-Oral Therapy

J. Reiling, E. Barr, E. Lawitz, 2016 .

Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial

A. Howe, E. Barr, E. Lawitz, 2017, Hepatology.

O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks

A. Howe, E. Barr, E. Lawitz, 2015 .

Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: A blind histologic study

A. Branch, T. Schiano, S. Thung, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Evaluation of Fatigue in U.S. Patients with Primary Biliary Cirrhosis

A. Branch, C. Bodian, P. Berk, 2005, The American Journal of Gastroenterology.

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials

V. de Lédinghen, M. Burroughs, M. Shiffman, 2021, Journal of viral hepatitis.

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin

E. Lawitz, F. Poordad, K. Speeg, 2017, Clinical case reports.

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

P. V. Remoortere, M. Gamil, E. Lawitz, 2020, Health science reports.

Treatment of patients with hepatitis C virus genotype 3: Where are we now?

F. Poordad, J. Wells, Carmen E. Landaverde, 2015, Clinical liver disease.

Eight Weeks Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.

V. de Lédinghen, F. Nevens, J. Dillon, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Ledipasvir/Sofosbuvir-Based Treatment of Patients with Chronic Genotype-1 HCV Infection and Cirrhosis: Results from Two Phase II Studies

H. Dvory‐Sobol, D. Brainard, J. McHutchison, 2016, Antiviral therapy.

Cost-Effectiveness of Hepatitis C Screening and Treatment in Low-Income, Primarily Hispanic Baby Boomers

C. Hollenbeak, B. Turner, J. Gutierrez, 2019, Journal of health care for the poor and underserved.

Human Peritoneal Macrophages From Ascitic Fluid Can be Infected by a Broad Range of HIV-1 Isolates

A. Branch, T. Schiano, Theresa L. Chang, 2010, Journal of acquired immune deficiency syndromes.

Cross-genotypic polyclonal anti-HCV antibodies from human ascitic fluid.

A. Branch, C. Rice, T. Schiano, 2011, Journal of virological methods.

640 HCV alternate reading frame proteins (ARFPS) may be virulence factors that help the virus survive adverse conditions

A. Branch, D. Dieterich, T. Schiano, 2003 .